Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2004

View Archived Issues

Statins reported to reduce blood pressure in nonhypertensive subjects

Pioglitazone improves insulin resistance and carotid IMT in type 2 diabetes

Clinical assessment of ABX-10241 in secondary hyperparathyroidism begins

TGN-255 investigated in two phase I studies

Encouraging phase I findings for DNA influenza vaccine

Phase II results from Altastaph neonate study

Restructuring at Tapestry

Viventia enhances phase I bladder cancer program for Proxinium

Xagrid approved in E.U.

Azilect recommended for approval in Europe

New NCI-sponsored study of GTI-2040 for prostate cancer

ISTA licenses U.S. rights for ecabet sodium for dry eye

Dosing commences in phase I study of LEraf-AON

Promising safety profile of a peginterferon/ribavirin/amantadine regimen in HIV/HCV coinfection

Positive opinion for Truvada in Europe

New orexin receptor antagonists claimed by Actelion

Melatonin derivatives for the treatment of neurological diseases

Roche researchers describe receptor tyrosine kinase inhibitors

New protein kinase inhibitors prepared and tested at Roche

Novel TPK1 inhibitors and their use in neurodegenerative diseases covered in patent

Raf-kinase inhibitors in early development at Merck

A topical gel containing rAAT shows a good tolerability profile in patients with atopic dermatitis

Emisphere signs agreement with Roche to develop oral formulations of compounds for bone diseases

IDEA-070 reduces inflammation and pain in UVB-induced sunburn

Update on the antitumor efficacy and safety of BAY-43-9006

HepeX-C development progresses

Symbollon receives Canadian authorities' guidance for IoGen

Tarceva approved for advanced NSCLC

Further data supporting link between Lp-PLA2 and risk of cardiovascular disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...